Miento: Maximising human phenotypic plasticity for the space environment

The space environment is an incredibly stressful environment for humans and other organic life forms adapted to Earth’s gravity. The human microbiome is integral to human growth and development, cognitive function, nutritional and immune status, and general health. The microbiome has two habitats: the skin and appendages and the oral-gastrointestinal tract, both are external to the human body and contain more genomic material by a large factor, than the entire human body. It can be argued that the uterus in females is a third habitat, it is technically external to the human body.

Spaceport Australia Pty Ltd has created a supplement to contribute to human health and functioning in the space environment. Elements of the supplement have been [clinically, peer reviewed] demonstrated to be anti-tumor, anti-cancer, anti-viral, anti-biotic, anti-inflammatory, bone mass protective and clinically supportive of the human immune system. It is anticipated that V/Q oxygen exchange in low oxygen environments (e.g. off-Earth habitats, space stations and spacecraft) will improve by 10%, helping to offset cognitive changes experienced in enclosed space environments.

The supplement has strong potential for adjuvant medical use on Earth.

• Investment to complete clinical trials and regulatory application (envisioned multiple jurisdictions).
• Return: % share of final product and sales commensurate to the level of investment to a maximum of 49% shareholding.